Professor
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece, Greece
Evangelos Terpos, MD, PhD is a Professor of Hematology and Director of Stem Cell Transplantation Unit in the Department of Clinical Therapeutics of the National & Kapodistrian University of Athens, School of Medicine, Athens, Greece.
His main research interest is the biology of plasma cell dyscrasias and especially the biology and management of bone disease in multiple myeloma. Dr Terpos has evaluated the effect of bisphosphonates, denosumab and different anti-myeloma therapies on bone metabolism of myeloma patients. He has studied the mechanisms and prevalence of osteonecrosis of the jaw in myeloma patients who receive bone-targeted agents and the role of modern imaging for diagnosis and follow-up of myeloma. He also evaluates the role of MRD in myeloma, biology and management of renal impairment in plasma cell neoplasms and, during COVID pandemic, the immune response after COVID-19 or vaccination against SARS-CoV-2.
In the clinical research era, Dr Terpos participates in several clinical trials with novel agents in the myeloma field, including immunotherapies targeting BCMA. His research work was reported in more than 750 papers in peer-reviewed journals and Dr Terpos has more 35,000 citations and an h-index of 85 in ISI/Web of Knowledge and more than 55,000 citations and an h-index of 108 in Google Scholar (March 2024).
Dr Terpos is co-chairing the Bone Sub-Committee of the International Myeloma Working Group and is a member of the Guideline Subgroup of the European Myeloma Network (EMN). He is also a member of the Publication Committee of the International Myeloma Society (IMS) and editor of the newsletter of the Society.
He has given lectures at ASH, ASCO, EHA & EMN meetings as well as in International Myeloma Workshops. He is Associate Editor of Clinical Lymphoma Myeloma & Leukemia (official journal of IMS) and of the American Journal of Hematology for Myeloma.